As we approach our 200th anniversary year in 2020, I am proud to announce a major milestone in USP’s publication history, the conclusion of the USP–NF printed product.

With significant innovations in pharmaceuticals, including biologic drugs and treatments for rare diseases, the need for new and better functioning excipients to improve drug delivery is growing.

What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?